# A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

Source: https://onco.cc/trials/nct06727630/  
OnCo record `nct06727630` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PRJ1-3024 in melanoma, run by Zhuhai Yufan Biotechnologies Co., Ltd, now recruiting.

## Summary

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06727630 by Zhuhai Yufan Biotechnologies Co., Ltd, with 40 participants planned, started 2024-03-14 and due to reach its primary completion in 2025-04-30. Interventions recorded: PRJ1-3024.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06727630
- Phase: 1/2
- Setting: A Phase Ib Study, Evaluating the Safety, Tolerance and Efficacy of PRJ1-3024 Capsules in China Subjects with Unresectable Local Advanced or Metastatic Melanoma
- Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06727630: https://clinicaltrials.gov/study/NCT06727630

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Zhuhai Yufan Biotechnologies](https://onco.cc/companies/zhuhai-yufan-biotechnologies/)

---
JSON: https://onco.cc/api/v1/entities/nct06727630.json